Browse by Research Team

Article

Passenger gene coamplifications create collateral therapeutic vulnerabilities in cancer.
Bei, Y., Brame, Luca, Kirchner, M., Fritsche-Guenther, R., Kunz, S., Bhattacharya, A., Rusu, M.C., Gürgen, D., Dubois, F.P.B., Köppke, J.K.C., Proba, J., Wittstruck, N., Sidorova, O.A., Chamorro González, R., Dorado Garcia, H., Brückner, L., Xu, R., Giurgiu, M., Rodriguez-Fos, E., Yu, Q., Spanjaard, B., Koche, R.P., Schmitt, C.A., Schulte, J.H., Eggert, A., Haase, K., Kirwan, J., Hagemann, A.I., Mertins, P., Dörr, J.R. and Henssen, A.G.
Cancer Discovery 14 (3): 492-507. 1 March 2024

Germline mutations including the rare pathogenic variant c.3206delC in the ATM gene cause ataxia teleangiectasia-associated primary central nervous system lymphoma.
Dörr, J.R., Thorwarth, A., Mizia-Malarz, A., Radke, J., Tietze, A., Hernáiz-Driever, P., Horn, D., Gratopp, A., Eggert, A. and Deubzer, H.E.
Children 8 (6): 469. June 2021

H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients.
Schleich, K., Kase, J., Dörr, J.R., Trescher, S., Bhattacharya, A., Yu, Y., Wailes, E.M., Fan, D.N.Y., Lohneis, P., Milanovic, M., Lau, A., Lenze, D., Hummel, M., Chapuy, B., Leser, U., Reimann, M., Lee, S. and Schmitt, C.A.
Nature Communications 11 (1): 3651. 20 July 2020

Senescence-associated reprogramming promotes cancer stemness.
Milanovic, M., Fan, D.N.Y., Belenki, D., Däbritz, J.H.M., Zhao, Z., Yu, Y., Dörr, J.R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I.A., Mendoza-Parra, M.A., Kanashova, T., Metzner, M., Pardon, K., Reimann, M., Trumpp, A., Dörken, B., Zuber, J., Gronemeyer, H., Hummel, M., Dittmar, G., Lee, S. and Schmitt, C.A.
Nature 553 (7686): 96-100. 4 January 2018

CD20-targeting immunotherapy promotes cellular senescence in B-cell lymphoma.
Däbritz, J.H.M., Yu, Y., Milanovic, M., Schönlein, M., Rosenfeldt, M.T., Dörr, J.R., Kaufmann, A.M., Dörken, B. and Schmitt, C.A.
Molecular Cancer Therapeutics 15 (5): 1074-1081. May 2016

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.
Dörr, J.R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J.H.M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., Kratzat, S., Purfürst, B., Walenta, S., Mueller-Klieser, W., Gräler, M., Hummel, M., Keller, U., Buck, A.K., Dörken, B., Willmitzer, L., Reimann, M., Kempa, S., Lee, S. and Schmitt, C.A.
Nature 501 (7467): 421-425. 19 September 2013

Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.
Jing, H., Kase, J., Dörr, J.R., Milanovic, M., Lenze, D., Grau, M., Beuster, G., Ji, S., Reimann, M., Lenz, P., Hummel, M., Doerken, B., Lenz, G., Scheidereit, C., Schmitt, C.A. and Lee, S.
Genes & Development 25 (20): 2137-2146. 15 October 2011

Tumor stroma-derived TGF-beta limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence.
Reimann, M., Lee, S., Loddenkemper, C., Dörr, J.R., Tabor, V., Aichele, P., Stein, H., Doerken, B., Jenuwein, T. and Schmitt, C.A.
Cancer Cell 17 (3): 262-272. 16 March 2010